Ixeris chinensis extract as well as preparation method, application and traditional Chinese medicine preparation thereof

By isolating polysaccharides, oligosaccharides and other components from water thirst extract, the problem of poor efficacy of the treatment of myocardial ischemia in the prior art was solved, and efficient and safe anti-heart failure effect was achieved, and the production process was simplified. , reduces costs.

CN118909151APending Publication Date: 2024-11-08ZHUHAI TENGBAI PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410809853.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-21
Filing Date
2024-06-21
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, the drug treatment effect of treating myocardial ischemia is poor or the material basis is unclear, and the production process is complex and the cost is high.

Method used

Polysaccharides, oligosaccharides, aromatic acids, cycloalether terpenes, phenylethanol glycosides and other components were isolated from the water-prone extract by macroporous resin or polyamide resin to verify their anti-heart failure efficacy.

Benefits of technology

The effective anti-heart failure area of ​​water-bearing sapling is clarified, and efficient and safe anti-heart failure drugs are provided, which simplifies the production process and reduces costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909151A_ABST
    Figure CN118909151A_ABST
Patent Text Reader

Abstract

The invention discloses an ixeris chinensis extract as well as a preparation method, application and a traditional Chinese medicine preparation thereof. The ixeris chinensis extract contains one or more of a polysaccharide active component, an oligosaccharide active component, an aromatic acid active component, an iridoid glycoside active component and a phenylethanoid glycoside active component. Large components such as polysaccharides, oligosaccharides, aromatic acids, phenylethanoid glycosides and iridoid glycosides are prepared from a water extract of a single traditional Chinese medicinal material ixeris chinensis through resin separation, and the protective effect on myocardial cell oxygen-glucose deprivation injury is verified on the in-vitro cell level. The in-vivo anti-heart-failure drug effect is verified on a left anterior descending branch ligation heart failure mouse model, so that the anti-heart-failure effective part of the ixeris chinensis is determined.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the priority of Chinese patent application CN2023107527664, filed on June 21, 2023. This application cites the full text of the above Chinese patent application. Technical Field

[0002] The invention relates to a water calamus extract, a preparation method and application thereof, and a traditional Chinese medicine preparation. Background Art

[0003] Heart failure (HF), also known as HF for short, refers to the inability to fully discharge venous return blood from the heart due to the impairment of the heart's contractile and / or diastolic functions, resulting in venous blood congestion and insufficient arterial blood perfusion, which in turn causes a syndrome of cardiac circulatory disorders. As the aging of my country's population continues to intensify, the number of patients with heart failure continues to rise. The "China Cardiovascular Health and Disease Report 2021" estimates that the number of patients with heart failure is as high as 8.9 million, which is a significant increase compared to the 4.5 million patients with heart failure estimated in the "China Cardiovascular Disease Report 2018". At the same time, as the terminal stage of many heart diseases, heart failure has a 5-year mortality rate of more than 50%, and the annual mortality rate of patients with severe heart failure is as high as 60%. About 1 / 3 of new patients with severe heart failure die within 6 months after diagnosis, and the 5-year survival rate is only less than 20%. In addition, the poor prognosis of patients with heart failure seriously affects the quality of life after discharge, and also leads to a high rate of re-hospitalization, which brings huge medical and economic burdens to patients and society.

[0004] Traditional Chinese medicine has the characteristics of multi-component, multi-target and good safety. It has unique therapeutic advantages for heart failure with complex pathogenesis and long course. In the concept of traditional Chinese medicine, heart failure is considered to be caused by deficiency of heart qi and yang, and blood stasis and water retention as the symptoms. "Qi deficiency, blood stasis and water retention" is the pathological and physiological process throughout the course of heart failure, and the other symptoms evolve and develop on this basis. Therefore, the prescriptions for the treatment of heart failure are mainly based on removing blood stasis and unblocking collaterals, replenishing qi and activating blood circulation, strengthening the spleen and kidney, warming yang and strengthening the spleen, nourishing yin and resolving phlegm, and combined with individual differences of patients, syndrome differentiation and treatment are carried out. Commonly used prescriptions include Zhenwu Decoction, Shengmai Drink, Baoyuan Decoction, Xuefu Zhuyu Decoction, Tingli Dazao Xiefei Decoction, Linggui Shugan Decoction, Taohong Siwu Decoction, Shenfu Decoction, etc.; Chinese patent medicines in the form of capsules or pills include Qishen Yiqi Dropping Pills, Fufang Danshen Dropping Pills, Shexiang Baoxin Pills, Qili Qiangxin Capsules, Shengmai Capsules, etc.; Chinese patent medicines in the form of injections include Shenmai Injection, Huangqi Injection, Shenfu Injection, Xinmailong Injection, etc., and there are few single-prescription drugs. Compared with compound drugs, it is easier to clarify the material basis and the mechanism of action of drugs for effective parts developed from single medicinal materials, and it is also easier to conduct quality control, thereby ensuring efficacy and safety.

[0005] Existing patent: New use of Chinese herbal medicine water lettuce for anti-heart failure (CN202011417172.0, 2022-06-07), provides a use of Chinese herbal medicine water lettuce for preparing a composition or preparation for anti-heart failure, wherein the compound or preparation is used for anti-heart failure. Experiments have shown that the active ingredients of the invention can effectively fight heart failure and at the same time cause less toxicity to the heart. However, the material basis for the anti-heart failure activity has not been further clarified, and the dosage is large, making it difficult to develop directly.

[0006] Existing patent: A composition of Eucommia components with myocardial protection and its preparation (CN201410706095.9, 2015-03-25), specifically relates to a composition of Eucommia components for treating cardiovascular diseases. The components of the composition are all from the traditional Chinese medicine Eucommia, and are specifically composed of 10-80% by weight of total flavonoids of Eucommia, 10-80% by weight of eucommia iridoids and 10-80% by weight of eucommia lignans. The weight percentage of the composition is preferably 20-40% by weight of total flavonoids of Eucommia, 40-60% by weight of eucommia iridoids and 20-50% by weight of eucommia lignans. The invention combines the single effective parts of Eucommia and adjusts the relevant weight ratio to obtain a composition of Eucommia components with clear efficacy and clinical development prospects. However, total flavonoids, terpenes and lignans of Eucommia ulmoides are obtained by three separate preparation methods, which are complicated and involve organic solvents other than ethanol. The residual organic solvents need to be investigated during the production process, and the production cost and environmental protection cost are high. Summary of the invention

[0007] The technical problem to be solved by the present invention is to overcome the defects of the drugs for treating myocardial ischemia in the prior art, that is, the therapeutic effect is poor or the material action basis is unclear, and to provide a water caltrop extract and its preparation method and application, and a Chinese medicine preparation.

[0008] The present invention separates and prepares polysaccharides, oligosaccharides, aromatic acids, cyclopentane glycosides, phenylethanoid glycosides, flavonoids and other major components from a Herba Sophorae Flavescentis extract (such as an alcohol extract or a water extract) by using a resin (such as a macroporous resin or a polyamide resin), and verifies the anti-heart failure efficacy thereof in vivo and in vitro.

[0009] The present invention provides a method for preparing a polysaccharide active ingredient, which comprises the following steps:

[0010] The water extract of Ilex polyphylla was subjected to macroporous adsorption resin chromatography, and the effluent, the water-washed portion and the eluted portion of the ethanol solution A1 were collected in sequence, and after being combined, they were concentrated and precipitated with alcohol, and the precipitated portion was the polysaccharide active ingredient;

[0011] The concentration of the ethanol solution A1 is 5-15%.

[0012] In some preferred embodiments of the present invention, the water extract of Ixoraciae Polygoni Multiflori is prepared by the following method:

[0013] Mix Ipomoea aquatica with water and extract to obtain the product.

[0014] Wherein, the plant source of the water hyacinth can be northern water hyacinth (Veronica anagallis-aquatica L.), a plant of the genus Veronica in the Plantaginaceae family; or, water hyacinth Veronica undulata Wall, a plant of the genus Veronica in the Plantaginaceae family.

[0015] Wherein, the mass ratio of the water spinach to the water may be 1:(10-40), for example, 1:(10-15).

[0016] Wherein, before the extraction, the water spinach can be soaked in water for 1-2 hours.

[0017] The extraction temperature may be 100-120°C, for example 110°C.

[0018] Wherein, the extraction method can be reflux extraction.

[0019] The extraction time may be 2-10 hours, such as 2 hours or 6 hours.

[0020] The extraction may be performed once or multiple times, for example, 3 times, each time for 2 hours. When the extraction is performed multiple times, the extracts may be combined to obtain the water extract of Sophora japonica L.

[0021] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example, 1:3.

[0022] In some preferred embodiments of the present invention, the model of the macroporous adsorption resin is HPD100.

[0023] In some preferred embodiments of the present invention, the concentration of the ethanol solution A1 is 10%.

[0024] In some preferred embodiments of the present invention, the concentration before alcohol precipitation is to about 1 / 10 of the original volume.

[0025] In some preferred embodiments of the present invention, the alcohol precipitation is carried out under the condition of an alcohol content of 70-80% (eg 75%), where the percentage refers to volume percentage.

[0026] In some preferred embodiments of the present invention, the alcohol precipitation time is standing at 4° C. overnight.

[0027] In some preferred embodiments of the present invention, the alcohol precipitation is followed by centrifugation, which may be performed at 4000 rpm for 20 min.

[0028] In some preferred embodiments of the present invention, the precipitate obtained after the alcohol precipitation can be re-dissolved in water to remove the alcohol solvent. After re-dissolving in water, the aqueous solution can be removed by freeze drying.

[0029] In some preferred embodiments of the present invention, the precipitation part is freeze-dried.

[0030] The present invention also provides a polysaccharide active ingredient, which is prepared by the above method.

[0031] The present invention also provides a method for preparing an oligosaccharide active ingredient, which comprises the following steps:

[0032] The water extract of Ilex polyphylla was subjected to macroporous adsorption resin chromatography, and the effluent, the water washing part and the elution part of the ethanol solution A2 were collected in sequence, and after the first combination, the supernatant was obtained after concentration and alcohol precipitation; the concentration of the ethanol solution A2 was 5-15%;

[0033] The supernatant is subjected to polyamide resin column chromatography, and the effluent and the water-washed portion are collected in sequence. After being combined for the second time, the supernatant is concentrated and optionally dried to obtain the oligosaccharide active ingredient.

[0034] In some preferred embodiments of the present invention, the preparation method of the Ipomoea aquatica aqueous extract is as described above.

[0035] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example, 1:3.

[0036] In some preferred embodiments of the present invention, the model of the macroporous adsorption resin is HPD100.

[0037] In some preferred embodiments of the present invention, the concentration of the ethanol solution A2 is 10%.

[0038] In some preferred embodiments of the present invention, the concentration before alcohol precipitation is to about 1 / 10 of the original volume.

[0039] In some preferred embodiments of the present invention, the alcohol precipitation is carried out under the condition of an alcohol content of 70-80% (eg 75%), where the percentage refers to volume percentage.

[0040] In some preferred embodiments of the present invention, the alcohol precipitation time is standing at 4° C. overnight.

[0041] In some preferred embodiments of the present invention, the alcohol precipitation is followed by centrifugation, which may be performed at 4000 rpm for 20 min.

[0042] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of I. polychosanthis used in the I. polychosanthis water extract to the polyamide resin is 1:(1-5), for example, 1:3.

[0043] In some preferred embodiments of the present invention, the particle size of the polyamide resin is 60-80 mesh.

[0044] In some preferred embodiments of the present invention, the drying method is freeze-drying.

[0045] The present invention also provides an oligosaccharide active ingredient, which is prepared by the above method.

[0046] The present invention also provides a method for preparing an aromatic acid active ingredient, which comprises the following steps:

[0047] The water extract of Ilex polyphylla was subjected to macroporous adsorption resin chromatography, and the effluent, the water washing part and the elution part of the ethanol solution A3 were collected in sequence, and after the first combination, the supernatant was obtained after concentration and alcohol precipitation; the ethanol concentration in the ethanol solution A3 was 5-15%;

[0048] The supernatant is chromatographed on a polyamide resin column, eluted with water, and the eluted portion of the ethanol solution B3 is collected, concentrated, and optionally dried to obtain the aromatic acid active ingredient; the concentration of ethanol in the ethanol solution B3 is 70-80%.

[0049] In some preferred embodiments of the present invention, the preparation method of the Ipomoea aquatica aqueous extract is as described above.

[0050] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example, 1:3.

[0051] In some preferred embodiments of the present invention, the model of the macroporous adsorption resin is HPD100.

[0052] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution A3 is 10%.

[0053] In some preferred embodiments of the present invention, the alcohol precipitation is carried out under the condition of an alcohol content of 70-80% (eg 75%), where the percentage refers to volume percentage.

[0054] In some preferred embodiments of the present invention, the alcohol precipitation time is standing at 4° C. overnight.

[0055] In some preferred embodiments of the present invention, the alcohol precipitation is followed by centrifugation, which may be performed at 4000 rpm for 20 min.

[0056] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of I. polychosanthis used in the I. polychosanthis water extract to the polyamide resin is 1:(1-5), for example, 1:3.

[0057] In some preferred embodiments of the present invention, the particle size of the polyamide resin is 60-80 mesh.

[0058] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution B3 is 75%.

[0059] In some preferred embodiments of the present invention, the drying method is freeze-drying.

[0060] The invention also provides an aromatic acid active ingredient, which is prepared by the method.

[0061] The present invention also provides a method for preparing an iridoid glycoside active ingredient, which comprises the following steps:

[0062] The water extract of Ilex polyphylla was subjected to macroporous adsorption resin chromatography, and after being eluted with water and ethanol solution A4 in sequence, the elution portion of ethanol solution B4 and the elution portion of ethanol solution C4 were collected in sequence to obtain a mixed solution A;

[0063] The mixed solution A is subjected to polyamide resin column chromatography, and the effluent, the water washing portion, the ethanol solution D4 elution portion, and the ethanol solution E4 elution portion are collected in sequence, and after being combined, concentrated, and optionally dried to obtain the iridoid glycoside active ingredient;

[0064] In the ethanol solution A4, the concentration of ethanol is 5-15%;

[0065] In the ethanol solution B4, the concentration of ethanol is 25-35%;

[0066] In the ethanol solution C4, the concentration of ethanol is 45-55%;

[0067] In the ethanol solution D4, the concentration of ethanol is 5-15%;

[0068] In the ethanol solution E4, the concentration of ethanol is 25-35%.

[0069] In some preferred embodiments of the present invention, the preparation method of the Ipomoea aquatica aqueous extract is as described above.

[0070] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example, 1:3.

[0071] In some preferred embodiments of the present invention, the model of the macroporous adsorption resin is HPD100.

[0072] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution A4 is 10%.

[0073] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution B4 is 30%.

[0074] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution C4 is 50%.

[0075] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of I. polychosanthis used in the I. polychosanthis water extract to the polyamide resin is 1:(1-5), for example, 1:2.

[0076] In some preferred embodiments of the present invention, the particle size of the polyamide resin is 60-80 mesh.

[0077] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution D4 is 10%.

[0078] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution E4 is 30%.

[0079] The present invention also provides an iridoid glycoside active ingredient, which is prepared by the above method.

[0080] The present invention also provides a method for preparing a phenylethanoid glycoside active ingredient, which comprises the following steps:

[0081] The water extract of Ilex polyphylla was subjected to macroporous adsorption resin chromatography, and after being eluted with water and ethanol solution A5 in sequence, the elution portion of ethanol solution B5 and the elution portion of ethanol solution C5 were collected in sequence to obtain a mixed solution A;

[0082] The mixed solution A is subjected to polyamide resin column chromatography, and is first eluted with water, ethanol solution D5, and ethanol solution E5 in sequence, and then the elution fractions of ethanol solution F5, ethanol solution G5, and ethanol solution H5 are collected in sequence, combined, concentrated, and optionally dried to obtain the phenylethanol glycoside active ingredient;

[0083] In the ethanol solution A5, the concentration of ethanol is 5-15%;

[0084] In the ethanol solution B5, the concentration of ethanol is 25-35%;

[0085] In the ethanol solution C5, the concentration of ethanol is 45-55%;

[0086] In the ethanol solution D5, the concentration of ethanol is 5-15%;

[0087] In the ethanol solution E5, the concentration of ethanol is 25-35%;

[0088] In the ethanol solution F5, the concentration of ethanol is 45-55%;

[0089] In the ethanol solution G5, the concentration of ethanol is 65-75%;

[0090] In the ethanol solution H5, the concentration of ethanol is 90-100%.

[0091] In some preferred embodiments of the present invention, the preparation method of the Ipomoea aquatica aqueous extract is as described above.

[0092] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example, 1:3.

[0093] In some preferred embodiments of the present invention, the model of the macroporous adsorption resin is HPD100.

[0094] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution A5 is 10%.

[0095] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution B5 is 30%.

[0096] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution C5 is 50%.

[0097] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of I. polychosanthis used in the I. polychosanthis water extract to the polyamide resin is 1:(1-5), for example, 1:2.

[0098] In some preferred embodiments of the present invention, the particle size of the polyamide resin is 60-80 mesh.

[0099] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution D5 is 10%.

[0100] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution E5 is 30%.

[0101] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution F5 is 50%.

[0102] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution G5 is 70%.

[0103] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution H5 is 95%.

[0104] The present invention also provides a phenylethanoid glycoside active ingredient, which is prepared by the above method.

[0105] The present invention also provides a method for preparing the active component E4', which comprises the following steps:

[0106] The water extract of Ilex polyphylla is subjected to macroporous adsorption resin chromatography, and after being eluted with water and ethanol solution A4' in sequence, the elution fractions of ethanol solution B4' and ethanol solution C4' are collected in sequence, combined, concentrated, and optionally dried to obtain the active component E4';

[0107] In the ethanol solution A4', the concentration of ethanol is 5-15%;

[0108] In the ethanol solution B4', the concentration of ethanol is 25-35%;

[0109] In the ethanol solution C4', the concentration of ethanol is 45-55%.

[0110] In some preferred embodiments of the present invention, the preparation method of the Ipomoea aquatica aqueous extract is as described above.

[0111] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example, 1:3.

[0112] In some preferred embodiments of the present invention, the model of the macroporous adsorption resin is HPD100.

[0113] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution A4' is 10%.

[0114] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution B4' is 30%.

[0115] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution C4' is 50%.

[0116] The present invention also provides an active component E4', which is prepared by the above method.

[0117] The present invention also provides a method for preparing the active component E6, which comprises the following steps:

[0118] The water extract of Ilex polyphylla was subjected to macroporous adsorption resin chromatography, and after being eluted with water, ethanol solution A6, ethanol solution B6 and ethanol solution C6 in sequence, the elution part of ethanol solution D6 and the elution part of ethanol solution E6 were collected to obtain a mixed solution B;

[0119] The mixed solution B is concentrated and optionally dried to obtain the active component E6;

[0120] In the ethanol solution A6, the concentration of ethanol is 5-15%;

[0121] In the ethanol solution B6, the concentration of ethanol is 25-35%;

[0122] In the ethanol solution C6, the concentration of ethanol is 45-55%;

[0123] In the ethanol solution D6, the concentration of ethanol is 65-75%;

[0124] In the ethanol solution E6, the concentration of ethanol is 90-100%.

[0125] In some preferred embodiments of the present invention, the preparation method of the Ipomoea aquatica aqueous extract is as described above.

[0126] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example, 1:3.

[0127] In some preferred embodiments of the present invention, the model of the macroporous adsorption resin is HPD100.

[0128] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution A6 is 10%.

[0129] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution B6 is 30%.

[0130] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution C6 is 50%.

[0131] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution D6 is 70%.

[0132] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution E6 is 95%.

[0133] The present invention also provides an active component E6, which is prepared by the above method.

[0134] In some preferred embodiments of the present invention, during the preparation of the polysaccharide active ingredient, the oligosaccharide active ingredient, the aromatic acid active ingredient, the iridoid glycoside active ingredient, the phenylethanoid glycoside active ingredient and the E6 active ingredient, the same or similar fractions can be combined according to the spectral absorption characteristic peaks or the liquid phase spectrum.

[0135] In some preferred embodiments of the present invention, the liquid phase spectrum is obtained using the following elution conditions:

[0136] Mobile phase A was 0.1% formic acid in water, and mobile phase B was acetonitrile;

[0137] Time min Mobile phase A% Mobile phase B% 0 85 15 22 85 15 30 50 50 31 5 95 35 5 95 .

[0138] Wherein, the flow rate of the mobile phase can be 1 mL / min.

[0139] In some preferred embodiments of the present invention, the liquid phase spectrum is obtained using a Waters Alliance 2695 high performance liquid chromatography system.

[0140] In some preferred embodiments of the present invention, the liquid phase spectrum is obtained by using a chromatographic column Unitray C18 (150×4.6mm id, 5.0μm, Huapu Xinchuang Technology Co., Ltd.)

[0141] In some preferred embodiments of the present invention, the liquid phase spectrum is obtained under the condition of a detection wavelength of 254 nm.

[0142] The present invention also provides a method for preparing the active ingredient of Ipomoea aquatica, which comprises the following steps:

[0143] The alcohol extract of Ipomoea aquatica was subjected to polyamide resin chromatography, and the effluent A, the elution part of ethanol solution B, the elution part of ethanol solution C, the elution part of ethanol solution D and the elution part of ethanol solution E were collected in sequence, and each eluate fraction was collected at an interval of 0.5-1.5 BV, and the same or similar fractions were combined according to the characteristic peaks of spectral absorption or liquid phase spectrum to obtain active ingredients F1, F2, F3, F4, F5;

[0144] In the ethanol solution B, the concentration of ethanol is 5-15%;

[0145] In the ethanol solution C, the concentration of ethanol is 25-35%;

[0146] In the ethanol solution D, the concentration of ethanol is 70-80%;

[0147] In the ethanol solution E, the concentration of ethanol is 90-100%.

[0148] In some preferred embodiments of the present invention, the Ipomoea aquatica ethanol extract is prepared by the following method:

[0149] The method is obtained by mixing Ilex polyphyllae with 70-80% (volume percentage) ethanol solution and performing extraction.

[0150] Wherein, the plant source of the water hyacinth can be northern water hyacinth (Veronica anagallis-aquatica L.), a plant of the genus Veronica in the Plantaginaceae family; or, water hyacinth Veronica undulata Wall, a plant of the genus Veronica in the Plantaginaceae family.

[0151] Wherein, the concentration of the ethanol solution may be 75%.

[0152] The ratio of the mass g of the Ipomoea aquatica to the volume ml of the ethanol solution may be (10-40):1, for example (10-15):1.

[0153] The extraction temperature may be 80-100°C, for example 95°C.

[0154] Wherein, the extraction method can be reflux extraction.

[0155] The extraction time may be 2-10 hours, such as 2 hours or 6 hours.

[0156] The extraction may be performed once or multiple times, for example, 3 times, each time for 2 hours. When the extraction is performed multiple times, the extracts may be combined to obtain the Ipomoea aquatica ethanol extract.

[0157] The alcohol extract of Ipomoea aquatica generally includes a concentration process after extraction, and the concentration can be concentrated by rotary evaporation at 65°C±5°C to a thick paste.

[0158] In some preferred embodiments of the present invention, the Ipomoea aquatica ethanol extract is obtained by dissolving the Ipomoea aquatica ethanol extract in a 5-15% (volume percentage) ethanol solution, such as 10% ethanol.

[0159] The ratio of the mass g of the Ipomoea aquatica ethanol extract to the volume mL of the ethanol solution may be 1:(20-40), for example, 1:30.

[0160] The dissolution may be carried out under ultrasonic conditions, for example, for 30 minutes.

[0161] After the dissolution, centrifugation may be further performed; for example, centrifugation at 4000 rpm for 20 min.

[0162] In some preferred embodiments of the present invention, the mass ratio of the crude drug amount (medicinal material amount) of Sophora japonica used in the Sophora japonica ethanol extract to the polyamide resin is 1:(1-5), for example, 1:3.

[0163] In some preferred embodiments of the present invention, the particle size of the polyamide resin is 60-80 mesh.

[0164] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution B is 10%.

[0165] In some preferred embodiments of the present invention, the elution volume of the ethanol solution B is 5-7 BV (column volume), for example 6 BV.

[0166] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution C is 30%.

[0167] In some preferred embodiments of the present invention, the elution volume of the ethanol solution C is 2-4 BV (column volume), for example 3 BV.

[0168] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution D is 75%.

[0169] In some preferred embodiments of the present invention, the elution volume of the ethanol solution D is 5-7 BV (column volume), for example 6 BV.

[0170] In some preferred embodiments of the present invention, the concentration of ethanol in the ethanol solution E is 95%.

[0171] In some preferred embodiments of the present invention, the elution volume of the ethanol solution E is 3-5 BV (column volume), for example 4 BV.

[0172] In some preferred embodiments of the present invention, each eluate fraction is collected at intervals of 1 BV.

[0173] In some preferred embodiments of the present invention, the spectral absorption characteristic peak is an ultraviolet absorption characteristic peak.

[0174] Wherein, the characteristic ultraviolet absorption peak can be measured at a wavelength of 200-600nm.

[0175] In some preferred embodiments of the present invention, the liquid phase spectrum is obtained using the following elution conditions:

[0176] Mobile phase A was 0.1% formic acid in water, and mobile phase B was acetonitrile;

[0177]

[0178]

[0179] Wherein, the flow rate of the mobile phase can be 1 mL / min.

[0180] In some preferred embodiments of the present invention, the liquid phase spectrum is obtained using a Waters Alliance 2695 high performance liquid chromatography system.

[0181] In some preferred embodiments of the present invention, the liquid phase spectrum is obtained by using a chromatographic column Unitray C18 (150×4.6mm id, 5.0μm, Huapu Xinchuang Technology Co., Ltd.)

[0182] In some preferred embodiments of the present invention, the liquid phase spectrum is obtained under the condition of a detection wavelength of 254 nm.

[0183] In some preferred embodiments of the present invention, the active ingredient F1, the active ingredient F2, the active ingredient F3, the active ingredient F4 and the active ingredient F5 are concentrated (eg, concentrated under reduced pressure at 55° C.) and dried before being processed.

[0184] The present invention also provides an active ingredient of Sophora japonica L., which comprises at least one of the active ingredient F1, the active ingredient F2, the active ingredient F3, the active ingredient F4 and the active ingredient F5.

[0185] The present invention also provides a water schizonepeta extract, which contains one or more of the polysaccharide active ingredients, the oligosaccharide active ingredients, the aromatic acid active ingredients, the iridoid glycoside active ingredients, the phenylethanoid glycoside active ingredients, the active component E6, the active component E4' and the water schizonepeta active ingredients.

[0186] The present invention also provides a traditional Chinese medicine preparation, which comprises the water spinach extract and pharmaceutically acceptable auxiliary materials.

[0187] In the present invention, the dosage form of the Chinese medicine preparation can be a conventional dosage form in the art, such as tablets, capsules, granules, etc.

[0188] In the present invention, "the sample effluent" refers to the liquid that flows out after the sample solution is adsorbed by the resin.

[0189] In the present invention, the concentration of ethanol refers to the volume percentage, for example, 10% ethanol means that 100 ml of ethanol solution contains 10 ml of ethanol.

[0190] In the present invention, the terms "first time" and "second time" have no special meanings and only indicate the order of mixing.

[0191] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0192] The reagents and raw materials used in the present invention are commercially available.

[0193] The positive and progressive effects of the present invention are:

[0194] The present invention prepares and separates polysaccharides, oligosaccharides, aromatic acids, phenylethanol glycosides, iridoid glycosides and other major components from a water extract of a single Chinese medicinal material, Herba Sophorae Flavescentis, by resin (e.g., macroporous resin or polyamide resin), verifies the protective effect on oxygen-glucose deprivation injury of myocardial cells at the in vitro cell level, verifies the in vivo anti-heart failure efficacy in a heart failure mouse model with ligation of the left anterior descending coronary artery, and further clarifies the effective anti-heart failure part of Herba Sophorae Flavescentis. BRIEF DESCRIPTION OF THE DRAWINGS

[0195] Figure 1 The UV absorption spectra of components E1-E6 in Example 1 at wavelengths of 200-600 nm.

[0196] Figure 2 This is a liquid phase analysis diagram of components E1-E6 in Example 1.

[0197] Figure 3 The UV absorption spectra of components F1-F5 in Example 6 at wavelengths of 200-600 nm.

[0198] Figure 4 This is the liquid phase analysis diagram of components F1-F5 in Example 6.

[0199] Figure 5 The in vivo efficacy of each major component under the MI model in Example 10; wherein: A: experimental model diagram; B: EF value of enrolled mice; C: change in EF value of mice after four weeks of administration; D: other cardiac function indicators of mice after four weeks of administration; E: exercise tolerance indicator of mice; ##P<0.01, ###P<0.001, ####P<0.0001vs Sham; *P<0.05, ****P<0.0001vs MI.

[0200] Figure 6 The in vivo efficacy of each major component under the MI model in Example 10; wherein: A: mouse heart-body ratio; B: mouse serum BNP content; C: WGA staining; D: Masson staining; #P<0.05, ####P<0.0001vs Sham; ****P<0.0001vsMI. DETAILED DESCRIPTION

[0201] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0202] In the following examples, the concentration of ethanol refers to volume percentage, for example, 10% ethanol means that 100 ml of ethanol solution contains 10 ml of ethanol.

[0203] Example 1 Preparation of water extract

[0204] Take 500g of dried medicinal materials of Veronica anagallis-aquatica L. (in this embodiment, the aerial part is used for extraction), cut into sections, add 10 times of water (mass ratio), soak for 1-2h, heat (110°C) and reflux extraction 3 times, each time for 2 hours, filter the extract, combine the filtrate and let it stand overnight, take the supernatant, centrifuge the lower solution, combine the supernatant, and obtain the water extract of Veronica anagallis-aquatica L. Take an appropriate amount of the extract, reduce pressure and concentrate, vacuum dry, obtain the extract powder, weigh it, and calculate the yield to be 29.03%. The calculation formula of the yield is: extract powder mass / medicinal material amount*100%.

[0205] Example 2 Preparation of major components E1-E6

[0206] (1) Take the water extract of Ipomoea aquatica in the above-mentioned Example 1, load it onto the pretreated HPD100 macroporous adsorption resin column (the crude drug (dried medicinal material of Ipomoea aquatica) in Example 1: resin = 1:3, mass ratio; HPD100 macroporous adsorption resin is a styrene-type non-polar copolymer), collect the load effluent; use water, 10% ethanol, 30% ethanol, 50% ethanol, 70% ethanol and 95% ethanol for elution in sequence. Obtain the water-washed portion, 10% ethanol-eluted portion, 30% ethanol-eluted portion, 50% ethanol-eluted portion, 70% ethanol-eluted portion and 95% ethanol-eluted portion, respectively.

[0207] Combine the sample effluent, the water-washed fraction and the 10% ethanol elution fraction, concentrate to a certain volume (concentrated to about 1 / 10 of the original volume), add ethanol to an alcohol content of 75%, stand at 4°C overnight, centrifuge at 4000rpm for 20min, add a small amount of water to the precipitate to re-dissolve, evaporate to release ethanol, and freeze-dry the solution to obtain component 1 (E1, polysaccharide active ingredients); concentrate the centrifugal supernatant, load it onto a pretreated polyamide column (the crude drug in Example 1 (dried medicinal material of Ipomoea aquatica): polyamide (the mesh number of polyamide is 60-80 mesh) = 1:3, mass ratio), collect the sample effluent; use water and 75% ethanol for elution in turn to obtain the water-washed fraction and the 75% ethanol elution fraction, respectively. Combine the sample effluent and the water-washed fraction, concentrate, and freeze-dry to obtain component 2 (E2, oligosaccharide active ingredients), and concentrate and freeze-dry the 75% ethanol elution fraction to obtain component 3 (E3, aromatic acid active ingredients).

[0208] Combine and concentrate the 30% ethanol elution fraction and the 50% ethanol elution fraction, load the fraction onto a pretreated polyamide column (crude drug (dried medicinal material of Ipomoea aquatica) in Example 1: polyamide (polyamide mesh number is 60-80 mesh) = 1:2, mass ratio), collect the load effluent; sequentially use water, 10% ethanol, 30% ethanol, 50% ethanol, 70% ethanol and 95% ethanol for elution. Obtain the water-wash fraction, 10% ethanol elution fraction, 30% ethanol elution fraction, 50% ethanol elution fraction, 70% ethanol elution fraction and 95% ethanol elution fraction, respectively. The loading effluent, water-washed fractions, 10% ethanol-eluted fractions and 30% ethanol-eluted fractions were combined, concentrated and freeze-dried to obtain component 4 (E4, an active ingredient of cyclopentane glycosides); the 50% ethanol-eluted fractions, 70% ethanol-eluted fractions and 95% ethanol-eluted fractions were combined, concentrated and freeze-dried to obtain component 5 (E5, an active ingredient of phenylethanoid glycosides).

[0209] The 70% ethanol elution fraction and the 95% ethanol elution fraction were combined, concentrated, and freeze-dried to obtain fraction 6 (E6). The yield of each fraction was calculated using the formula: mass of each fraction / mass of extract powder*100%.

[0210] (2) Take the water extract of Ipomoea aquatica in the above-mentioned Example 1, load it onto the pretreated HPD100 macroporous adsorption resin column (the crude drug in Example 1 (dried Ipomoea aquatica) : resin = 1:3, mass ratio; HPD100 macroporous adsorption resin is a styrene-type non-polar copolymer), collect the loaded effluent; use water, 10% ethanol, 30% ethanol, 50% ethanol, 70% ethanol and 95% ethanol for elution in sequence. Obtain the water-washed portion, 10% ethanol-eluted portion, 30% ethanol-eluted portion, 50% ethanol-eluted portion, 70% ethanol-eluted portion and 95% ethanol-eluted portion respectively. Combine and concentrate the 30% ethanol-eluted portion and the 50% ethanol-eluted portion to obtain a mixed solution, which is concentrated and freeze-dried to obtain component 4' (E4', a mixed component of iridoid glycoside active ingredients and phenylethanol glycoside active ingredients).

[0211] Table 1 Yield of components E1-E6

[0212] Components Yield Component 1, E1 20.76% Component 2, E2 48.22% Component 3, E3 3.65% Component 4, E4 16.54% Component 5, E5 3.07% Component 6, E6 1.51%

[0213] Example 3 UV absorption analysis of major components E1-E6

[0214] Take samples of components 1-6 (E1, E2, E3, E4, E5, E6) in Example 2, dissolve them in solvents respectively, take 2.5 mL and add them to a cuvette, use the solvent as a reference solution, and measure the absorbance at a wavelength of 200-600 nm using an ultraviolet spectrophotometer. The results are shown in Figure 1 .

[0215] according to Figure 1 The ultraviolet absorption spectra of components E1, E2, E3, E4, E5 and E6 in Example 2 at a wavelength of 200-600 nm, combined with the preparation method, can preliminarily determine that E1 is a polysaccharide active ingredient, E2 is an oligosaccharide active ingredient, E3 is an aromatic acid active ingredient, E4 is an iridoid glycoside active ingredient, and E5 is a phenylethanoid glycoside active ingredient.

[0216] Example 4 Liquid Phase Analysis of Major Components E1-E6

[0217] 4.1 Preparation of test solution

[0218] Take about 1.0 mg of the sample of component 1 to component 6 (E1, E2, E3, E4, E5, E6) in Example 2 respectively, weigh accurately, add 1 ml of methanol respectively, treat with ultrasound (power 250 W, frequency 40 KHZ) for 30 minutes, filter, and transfer to a liquid phase bottle.

[0219] 4.2 Liquid phase conditions

[0220] A Waters Alliance 2695 high performance liquid chromatography system was used, and the chromatographic column was Unitray C18 (150×4.6mm id, 5.0μm, Huapu Xinchuang Technology Co., Ltd.). Mobile phase A was 0.1% formic acid aqueous solution, mobile phase B was acetonitrile, injection volume was 10 μL, flow rate was 1 mL / min, and detection wavelength was 254 nm.

[0221] Table 2 Liquid phase analysis gradient elution program

[0222]

[0223] 4.3 Experimental Results

[0224] See Figure 2 .

[0225] according to Figure 2 It can be seen that components 1-6 (E1, E2, E3, E4, E5, E6) in Example 2 contain different active ingredients.

[0226] Example 5 Protective effects of major components E1-E6 on cardiomyocytes

[0227] 5.1 Experimental Methods

[0228] After the cultured rat cardiomyocytes H9c2 (2-1) were digested and counted, they were inoculated into 96-well plates at a number of 12,000 / well. After the cells grew to a density of 70-80%, the mother solution of components 1-6 was diluted to the required concentration and added to the well plate for pretreatment. After 12 hours, the culture medium of the modeling group was replaced with a PBS solution containing components 1-6 at the corresponding concentrations, and the well plate was placed in an anoxic chamber. After N2 replaced the air, the anoxic chamber was returned to the cell culture incubator for further culture for 3 hours. The cells of the control group continued to be cultured normally in the cell culture incubator. After the modeling was completed, the supernatant was discarded, 100 μL CCK-8 detection solution was added to each well, and the cells were incubated in a 37°C incubator in the dark for 2 hours, and the absorbance value (OD value) at a wavelength of 450 nm was detected by an enzyme marker.

[0229] 5.2 Data processing

[0230] Cell survival rate (%) = [(OD OGD处理组 -OD 溶剂对照 ) / (OD 正常对照组 -OD 溶剂对照 )] × 100%. GraphPadPrism 7 software was used to statistically analyze the experimental results, and the experimental results were expressed as mean ± standard error. Unpaired t test was used for inter-group comparison. *: significant difference relative to the model group; *: p < 0.05, **: p < 0.01, ***: p < 0.001.

[0231] 5.3 Experimental Results

[0232] The effects of each component on the survival rate of cardiomyocytes under the OGD model are shown in Table 3. The results showed that the cell survival rate in the model group was lower than that in the normal control group, indicating that the model was successfully established. Each component can significantly increase the cell survival rate at a certain concentration, indicating that each component has a protective effect on cardiomyocytes.

[0233] Table 3 Cell survival rate

[0234]

[0235] Example 6 Preparation of alcohol extract

[0236] Take 500 g of dried medicinal material of Veronica anagallis-aquatica L. (the aerial part is used for extraction in this embodiment), cut it into sections, add 10 times the amount of 75% ethanol (g / ml, add 10 ml of 75% ethanol for every 1 g of medicinal material), reflux and extract 3 times at 95°C, each time for 2 hours, combine the extracts and concentrate them at 65°C±5°C by rotary evaporation to a thick paste, vacuum dry and crush to obtain 116 g of extract powder, with a yield of 23.20%, and the yield is calculated as follows: extract powder mass / medicinal material amount*100%.

[0237] 1) Weigh 10 g of 75% ethanol extract powder, add 300 mL of 10% ethanol solution, ultrasonicate for 30 min, centrifuge at 4000 rpm for 20 min. Take the supernatant as the sample solution.

[0238] 2) The pretreated polyamide (particle size of 60-80 mesh) is loaded into a column (column volume of 300 mL). The filtrate of the sample solution in step 1) is loaded (the crude drug (dried medicinal material of Sophora flavescens) in Example 6: polyamide = 1:3, mass ratio), and the column liquid (i.e., the effluent) is collected. Then, the polyamide column is eluted with 10% (6BV), 30% (3BV), 75% ethanol (6BV) and 95% ethanol (4BV), respectively, and each eluate fraction is collected at intervals of 1BV, and samples are retained for ultraviolet analysis, and fractions with the same or similar ultraviolet absorption are combined (ultraviolet absorption conditions can be found in Example 8), or fractions with the same or similar liquid chromatograms are combined according to the liquid phase results (liquid phase conditions can be found in Example 9). Then, the mixture is concentrated and dried under reduced pressure at 55°C, and freeze-dried to obtain components 1-5 (F1-F5).

[0239] Table 4 Yield of components F1-F5

[0240] Components Yield Component 1, F1 41.84% Component 2, F2 25.25% Component 3, F3 4.60% Component 4, F4 3.80% Component 5, F5 2.74%

[0241] Example 7 Protective effects of components F1-F5 on cardiomyocytes

[0242] The experimental method and data processing are the same as those in Example 5.

[0243] The experimental results are shown in Table 5 below.

[0244] The effects of components F1-F5 in Example 6 on the survival rate of cardiomyocytes under the OGD model are shown in Table 5. The results show that the cell survival rate in the model group is lower than that in the normal control group, indicating that the modeling is successful. Each component can significantly increase the cell survival rate at a certain concentration, indicating that each component has a protective effect on cardiomyocytes.

[0245] Table 5 Cell viability

[0246]

[0247]

[0248] Example 8 UV absorption analysis of major components F1-F5

[0249] Take the samples of components F1-F5 in Example 6, dissolve them in solvent respectively, take 2.5 mL and add them to the cuvette, use the solvent as the reference solution, and measure the absorbance at a wavelength of 200-600 nm with an ultraviolet spectrophotometer. Figure 3 .

[0250] according to Figure 3 The ultraviolet absorption spectra of components F1-F5 in Example 6 at wavelengths of 200-600 nm, combined with the preparation method, can be preliminarily judged that F1-F5 contain different active ingredients.

[0251] Example 9 Liquid Phase Analysis of Major Components F1-F5

[0252] The preparation and liquid phase conditions of the test solution are the same as those in Example 4. The liquid chromatogram is shown in Figure 4 .

[0253] according to Figure 4 It can be seen that components F1-F5 in Example 6 contain different active ingredients.

[0254] Example 10 In vivo anti-heart failure efficacy test of components E1, E2, E3, E4' and E6 The efficacy test of this example adopts the left anterior descending coronary artery ligation model, and the specific experimental method is as follows:

[0255] After 8-10 weeks of adaptive breeding of C57 male mice, the neck and left chest of the mice were depilated with isoflurane-assisted anesthesia, and then the mice were fixed in a supine position, the neck skin was cut, the muscle layer was separated to expose the trachea, and the endotracheal tube was inserted through the mouth and connected to the ventilator. After the spontaneous breathing of the mice was synchronized with the ventilator, the mice were adjusted to the right side lying position, the surgical area was disinfected with iodine, and the second to third intercostal space was used as a hand incision. The skin and pectoralis major were cut in turn to expose the ribs, the pleura was opened, and the chest was expanded with a thoracotomy device. The pericardium was cut open to fully expose the heart, and the left anterior descending branch of the coronary artery was ligated with a non-invasive suture 2 to 3 mm below the junction of the pulmonary artery cone and the left atrial appendage. The myocardial color became pale and the pulsation weakened below the ligation site as a sign of successful modeling.

[0256] Unlike the previous practice of administering the drug immediately after surgery, the drug is now administered after the model is established (the administration time is when the mouse EF decreases significantly, see Figure 5 B), the dosing cycle is 4 weeks ( Figure 5 A). Five days after the ligation operation, the cardiac function of the surviving mice was examined (the survival rate was 50.7%). The EF was used as the standard to determine whether the MI mice had established a model. The established mice were evenly divided into 6 groups to ensure that there was no difference between the groups ( Figure 5 B). From the 6th day after surgery, each group of mice was gavaged with the solvent or the corresponding component (no medication was given from 0 to 5 days after surgery, and the medication frequency was once a day from the 6th day after surgery). The actual dosage of each component in Example 2 was converted to 25 g / kg of crude drug as shown in Table 6.

[0257] Table 6 Dosage of each component

[0258] Sample No. Dosage g / kg E1 1.18 E2 2.53 E3 0.065 E4’ 1.03 E6 0.048

[0259] (1) After 4 weeks of drug administration, the cardiac function of mice in each group was tested. For specific data, see Table 7, Table 8, Table 9 and Figure 5 .

[0260] in:

[0261] EF%: the percentage of diastolic blood volume ejected from the left ventricle during systole;

[0262] FS%: left ventricular fractional shortening;

[0263] LVEDV (μL): left ventricular end-diastolic volume;

[0264] LVESV (μL): left ventricular end-systolic volume;

[0265] Maximum gripping force: The instantaneous maximum gripping force of the mouse forelimbs was tested using the Shanghai Xinruan XR501 rat and mouse grip force meter.

[0266] Grasping time: the total time that the mouse's forelimbs grasped the test bar.

[0267] Rotarod time: The total time that mice exercise on the rotarod instrument. The test was conducted using a small animal rotarod fatigue instrument, and the rotation speed of the rotarod was 30 revolutions per minute.

[0268] Table 7 Comparison of FE% values ​​of mice in each group

[0269]

[0270] Note: In the above table, ####P<0.0001vs Sham

[0271] Table 8 Comparison of FE% values, LVESV and LVESD values ​​of mice in each group

[0272] Group FS% LVESV (μL) LVEDV (μL) Sham operation group 38.97±6.23 16.48±5.03 54.16±4.38 MI 12.91±8.73#### 114.5±72.74## 145.20±66.37## E1 14.07±13.13 149.2±110.0 181.3±107.5 E2 12.35±9.21 100.6±54.15 125.9±50.10 E3 21.10±14.90 82.98±74.09 113.3±74.72 E4’ 17.13±9.55 97.20±91.11 130.5±89.22 E6 16.73±9.98 89.99±67.01 121.6±64.67

[0273] Note: In the above table, ##P<0.01, ####P<0.0001vs Sham.

[0274] Table 9 Comparison of exercise tolerance indexes among mice in each group

[0275] Group Maximum grip force(gf) Grip duration(s) Rotation time (s) Sham operation group 193.40±17.73 1.13±0.12 212.70±86.08 MI 155.70±24.80## 0.87±0.06### 178.50±109.40 E1 159.80±34.44 0.94±0.13 206.00±129.20 E2 176.50±19.77 0.81±0.12 161.20±121.20 E3 166.40±24.31 0.77±0.06 256.00±57.60 E4’ 190.10±21.64* 1.84±0.22**** 262.00±70.38 E6 188.60±15.93* 1.36±0.08**** 231.00±84.27

[0276] Note: In the above table, ##P<0.01, ###P<0.001vs Sham; *P<0.05, ****P<0.0001vs MI.

[0277] The results are shown in Tables 7, 8, 9 and Figure 5 As shown. Figure 5 B- Figure 5 As shown in D, the EF value of mice in the MI group did not deteriorate significantly, and the cardiac function indicators of E1 and E2 were comparable to those of the MI group. E3, E4', and E6 all showed a certain degree of improvement compared with MI, among which the improvement of E3 was the most obvious. In terms of exercise tolerance indicators, mice in the E4' and E6 groups showed a significant improvement in maximum grip force and grip duration, while E3 did not show an improvement trend. In the rotating rod model, E3, E4', and E6 could prolong the time mice could exercise on the rod ( Figure 5 E). That is, although E3, E4', and E6 failed to significantly improve cardiac function, they significantly improved the exercise tolerance of mice. In this regard, E4' had the best effect.

[0278] (2) After completing the behavioral tests in (1), the mice in each group were dissected and samples were collected.

[0279] Serum B-type natriuretic peptide (BNP) is a neurohormone secreted by myocardial cells, which has the effects of diuresis, sodium secretion, vasodilation, lowering blood pressure, inhibiting the renin-angiotensin-aldosterone system and antidiuretic hormone, etc. Its determination was carried out according to the operating procedures of the ELISA detection kit, and the mouse brain natriuretic peptide / brain natriuretic peptide (BNP) detection kit was purchased from Shanghai Ruifan Biotechnology Co., Ltd.

[0280] Table 10 Heart-body ratio and serum BNP content of mice in each group

[0281]

[0282]

[0283] Note: In the above table, #P<0.05, ####P<0.0001vs Sham; ****P<0.0001vs MI.

[0284] The heart-body ratio and serum BNP content of each group of mice are shown in Table 10 and Figure 6 shown. Specifically:

[0285] Record the heart mass of mice and calculate the heart-body ratio ( Figure 6 A), the increase of the heart-body ratio in the MI group was not very significant, and only E6 showed a slight downward trend in each group. However, from the BNP content in serum, it can be seen that E1-E3, E4', and E6 can significantly reduce the increase in BNP content caused by MI, among which the efficacy of E1 and E4' groups is the most significant ( Figure 6 B).

[0286] In addition, pathological analysis was performed on the heart sections of each group of mice. Wheat germ agglutinin (WGA) staining can specifically bind to the glycoprotein on the myocardial cell membrane and fluorescently stain the myocardial cell membrane, which can be used to determine whether myocardial cells are hypertrophic or other pathological conditions. Masson staining can show the fiber components in the tissue, with collagen fibers appearing blue and muscle fibers appearing red.

[0287] like Figure 6 As shown in C, the area of ​​myocardial cells in the MI group was significantly larger than that in the Sham group. E1-E3 also showed the phenotype of myocardial hypertrophy. The area of ​​myocardial cells in the E4' and E6 groups was significantly reduced, and the reduction in E4' was more obvious. This suggests that E4' and E6 may have the effect of improving ventricular remodeling. Figure 6 As shown in D, the blue color of E4' and E6 was reduced, indicating that myocardial fibrosis induced by MI was improved.

[0288] Based on the above experimental results, it can be clearly seen that:

[0289] The anti-heart failure efficacy of components E1 and E2 is relatively weak, while E3, E4' and E6 all have certain anti-heart failure efficacy, among which E4' has the most significant efficacy.

Claims

1. A method for preparing a polysaccharide active ingredient, characterized in that: It includes the following steps: The water extract of Ilex polyphylla is subjected to macroporous adsorption resin chromatography, and the effluent, the water-washed portion and the eluted portion of the ethanol solution A1 are collected in sequence, and after being combined, concentrated and precipitated with alcohol, the precipitated portion is the polysaccharide active ingredient; The concentration of the ethanol solution A1 is 5-15%; Preferably, the method for preparing the polysaccharide active ingredient meets one or more of the following conditions: ① The water extract of Ixora solani is prepared by the following method: Mix Ipomoea aquatica with water and extract it to obtain the product; The mass ratio of the water calamus to the water may be 1:(10-40); The extraction temperature may be 100-120°C, for example 110°C; The extraction method can be reflux extraction; The extraction time may be 2-10 hours, for example 2 hours or 6 hours; ② The mass ratio of the crude drug amount of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example 1:3; ③ The model of the macroporous adsorption resin is HPD100; ④ The concentration of the ethanol solution A1 is 10%; ⑤ The alcohol precipitation is carried out under the condition of 70-80% alcohol content, and the percentage refers to the volume percentage; ⑥ The alcohol precipitation time is 4°C overnight; ⑦ After the alcohol precipitation, centrifugation is further performed; the centrifugation condition can be centrifugation at 4000 rpm for 20 minutes.

2. A polysaccharide active ingredient, which is prepared by the preparation method of the polysaccharide active ingredient according to claim 1.

3. A method for preparing an oligosaccharide active ingredient, characterized in that: It includes the following steps: The water extract of Ilex polyphylla was subjected to macroporous adsorption resin chromatography, and the effluent, the water-washed portion and the eluted portion of the ethanol solution A2 were collected in sequence, and after the first combination, the supernatant was collected after concentration and alcohol precipitation; The concentration of the ethanol solution A2 is 5-15%; The supernatant is subjected to polyamide resin column chromatography, the effluent and the water-washed portion are collected in sequence, and after a second combination, they are concentrated and optionally dried to obtain the oligosaccharide active ingredient; Preferably, the method for preparing the oligosaccharide active ingredient meets one or more of the following conditions: ① The water extract of Ixora solani is prepared by the following method: Mix Ipomoea aquatica with water and extract it to obtain the product; The mass ratio of the water calamus to the water may be 1:(10-40); The extraction temperature may be 100-120°C, for example 110°C; The extraction method can be reflux extraction; The extraction time may be 2-10 hours, for example 2 hours or 6 hours; ② The mass ratio of the crude drug amount of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example 1:3; ③ The model of the macroporous adsorption resin is HPD100; ④ The concentration of the ethanol solution A2 is 10%; ⑤ The alcohol precipitation is carried out under the condition of 70-80% alcohol content, and the percentage refers to the volume percentage; ⑥ The alcohol precipitation time is 4°C overnight; ⑦ After the alcohol precipitation, centrifugation is further performed; the centrifugation condition may be centrifugation at 4000 rpm for 20 minutes; ⑧ The mass ratio of the crude drug amount of I. polytrichum used in the I. polytrichum aqueous extract to the polyamide resin is 1:(1-5), for example 1:3; ⑨The particle size of the polyamide resin is 60-80 mesh.

4. An oligosaccharide active ingredient, which is prepared by the method for preparing an oligosaccharide active ingredient according to claim 3.

5. A method for preparing an aromatic acid active ingredient, characterized in that: It includes the following steps: The water extract of Ilex polyphylla was subjected to macroporous adsorption resin chromatography, and the effluent, the water washing part and the elution part of ethanol solution A3 were collected in sequence, and after the first combination, the supernatant was collected after concentration and alcohol precipitation; In the ethanol solution A3, the concentration of ethanol is 5-15%; The supernatant is subjected to polyamide resin column chromatography, eluted with water, and the eluted portion of the ethanol solution B3 is collected, concentrated, and optionally dried to obtain the aromatic acid active ingredient; In the ethanol solution B3, the concentration of ethanol is 70-80%; Preferably, the preparation method of the aromatic acid active ingredient meets one or more of the following conditions: ① The water extract of Ixora solani is prepared by the following method: Mix Ipomoea aquatica with water and extract it to obtain the product; The mass ratio of the water calamus to the water may be 1:(10-40); The extraction temperature may be 100-120°C, for example 110°C; The extraction method can be reflux extraction; The extraction time may be 2-10 hours, for example 2 hours or 6 hours; ② The mass ratio of the crude drug amount of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example 1:3; ③ The model of the macroporous adsorption resin is HPD100; ④ In the ethanol solution A3, the concentration of ethanol is 10%; ⑤ The alcohol precipitation is carried out under the condition of 70-80% alcohol content, and the percentage refers to the volume percentage; ⑥ The alcohol precipitation time is 4°C overnight; ⑦ After the alcohol precipitation, centrifugation is further performed; the centrifugation condition may be centrifugation at 4000 rpm for 20 minutes; ⑧ The mass ratio of the crude drug amount of I. polytrichum used in the I. polytrichum aqueous extract to the polyamide resin is 1:(1-5), for example 1:3; ⑨The particle size of the polyamide resin is 60-80 mesh; ⑩ In the ethanol solution B3, the concentration of ethanol is 75%.

6. An aromatic acid active ingredient, which is prepared by the method for preparing an aromatic acid active ingredient according to claim 5.

7. A method for preparing an iridoid glycoside active ingredient, characterized in that: It includes the following steps: The water extract of Ilex polyphylla was subjected to macroporous adsorption resin chromatography, and after being eluted with water and ethanol solution A4 in sequence, the elution portion of ethanol solution B4 and the elution portion of ethanol solution C4 were collected in sequence to obtain a mixed solution A; The mixed solution A is subjected to polyamide resin column chromatography, and the effluent, the water washing portion, the ethanol solution D4 elution portion, and the ethanol solution E4 elution portion are collected in sequence, and after being combined, concentrated, and optionally dried to obtain the iridoid glycoside active ingredient; In the ethanol solution A4, the concentration of ethanol is 5-15%; In the ethanol solution B4, the concentration of ethanol is 25-35%; In the ethanol solution C4, the concentration of ethanol is 45-55%; In the ethanol solution D4, the concentration of ethanol is 5-15%; In the ethanol solution E4, the concentration of ethanol is 25-35%; Preferably, the preparation method of the iridoid glycoside active ingredient meets one or more of the following conditions: ① The water extract of Ixora solani is prepared by the following method: Mix Ipomoea aquatica with water and extract it to obtain the product; The mass ratio of the water calamus to the water may be 1:(10-40); The extraction temperature may be 100-120°C, for example 110°C; The extraction method can be reflux extraction; The extraction time may be 2-10 hours, for example 2 hours or 6 hours; ② The mass ratio of the crude drug amount of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example 1:3; ③ The model of the macroporous adsorption resin is HPD100; ④ In the ethanol solution A4, the concentration of ethanol is 10%; ⑤ In the ethanol solution B4, the concentration of ethanol is 30%; ⑥ In the ethanol solution C4, the concentration of ethanol is 50%; ⑦ The mass ratio of the crude drug amount of I. polytrichum used in the I. polytrichum aqueous extract to the polyamide resin is 1:(1-5), for example 1:2; ⑧ The particle size of the polyamide resin is 60-80 mesh; ⑨ In the ethanol solution D4, the concentration of ethanol is 10%; ⑩ In the ethanol solution E4, the concentration of ethanol is 30%.

8. An iridoid glycoside active ingredient, which is prepared by the preparation method of the iridoid glycoside active ingredient according to claim 7.

9. A method for preparing a phenylethanoid glycoside active ingredient, characterized in that: It includes the following steps: The water extract of Ilex polyphylla was subjected to macroporous adsorption resin chromatography, and after being eluted with water and ethanol solution A5 in sequence, the elution portion of ethanol solution B5 and the elution portion of ethanol solution C5 were collected in sequence to obtain a mixed solution A; The mixed solution A is subjected to polyamide resin column chromatography, and is first eluted with water, ethanol solution D5, and ethanol solution E5 in sequence, and then the elution fractions of ethanol solution F5, ethanol solution G5, and ethanol solution H5 are collected in sequence, combined, concentrated, and optionally dried to obtain the phenylethanol glycoside active ingredient; In the ethanol solution A5, the concentration of ethanol is 5-15%; In the ethanol solution B5, the concentration of ethanol is 25-35%; In the ethanol solution C5, the concentration of ethanol is 45-55%; In the ethanol solution D5, the concentration of ethanol is 5-15%; In the ethanol solution E5, the concentration of ethanol is 25-35%; In the ethanol solution F5, the concentration of ethanol is 45-55%; In the ethanol solution G5, the concentration of ethanol is 65-75%; In the ethanol solution H5, the concentration of ethanol is 90-100%; Preferably, the preparation method of the phenylethanoid glycoside active ingredient meets one or more of the following conditions: ① The water extract of Ixora solani is prepared by the following method: Mix Ipomoea aquatica with water and extract it to obtain the product; The mass ratio of the water calamus to the water may be 1:(10-40); The extraction temperature may be 100-120°C, for example 110°C; The extraction method can be reflux extraction; The extraction time may be 2-10 hours, for example 2 hours or 6 hours; ② The mass ratio of the crude drug amount of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example 1:3; ③ The model of the macroporous adsorption resin is HPD100; ④ In the ethanol solution A5, the concentration of ethanol is 10%; ⑤ In the ethanol solution B5, the concentration of ethanol is 30%; ⑥ In the ethanol solution C5, the concentration of ethanol is 50%; ⑦ The mass ratio of the crude drug amount of I. polytrichum used in the I. polytrichum aqueous extract to the polyamide resin is 1:(1-5), for example 1:2; ⑧ The particle size of the polyamide resin is 60-80 mesh; ⑨ In the ethanol solution D5, the concentration of ethanol is 10%; ⑩ In the ethanol solution E5, the concentration of ethanol is 30%; ⑾ In the ethanol solution F5, the concentration of ethanol is 50%; ⑿ In the ethanol solution G5, the concentration of ethanol is 70%; ⒀In the ethanol solution H5, the concentration of ethanol is 95%.

10. A phenylethanoid glycoside active ingredient, which is prepared by the preparation method of the phenylethanoid glycoside active ingredient according to claim 9.

11. A method for preparing active ingredient E6, characterized in that: It includes the following steps: The water extract of Ilex polyphylla was subjected to macroporous adsorption resin chromatography, and after being eluted with water, ethanol solution A6, ethanol solution B6 and ethanol solution C6 in sequence, the elution part of ethanol solution D6 and the elution part of ethanol solution E6 were collected to obtain a mixed solution B; The mixed solution B is concentrated and optionally dried to obtain the active component E6; In the ethanol solution A6, the concentration of ethanol is 5-15%; In the ethanol solution B6, the concentration of ethanol is 25-35%; In the ethanol solution C6, the concentration of ethanol is 45-55%; In the ethanol solution D6, the concentration of ethanol is 65-75%; In the ethanol solution E6, the concentration of ethanol is 90-100%; Preferably, the preparation method of the active component E6 satisfies one or more of the following conditions: ① The water extract of Ixora solani is prepared by the following method: Mix Ipomoea aquatica with water and extract it to obtain the product; The mass ratio of the water calamus to the water may be 1:(10-40); The extraction temperature may be 100-120°C, for example 110°C; The extraction method can be reflux extraction; The extraction time may be 2-10 hours, for example 2 hours or 6 hours; ② The mass ratio of the crude drug amount of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example 1:3; ③ The model of the macroporous adsorption resin is HPD100; ④ In the ethanol solution A6, the concentration of ethanol is 10%; ⑤ In the ethanol solution B6, the concentration of ethanol is 30%; ⑥ In the ethanol solution C6, the concentration of ethanol is 50%; ⑦ In the ethanol solution D6, the concentration of ethanol is 70%; ⑧ In the ethanol solution E6, the concentration of ethanol is 95%.

12. An active component E6, which is prepared by the preparation method of the active component E6 according to claim 11.

13. A method for preparing an active ingredient of Ipomoea aquatica, characterized in that: It includes the following steps: The alcohol extract of Ipomoea aquatica was subjected to polyamide resin chromatography, and the effluent A, the elution part of ethanol solution B, the elution part of ethanol solution C, the elution part of ethanol solution D and the elution part of ethanol solution E were collected in sequence, and each eluate fraction was collected at an interval of 0.5-1.5 BV, and the same or similar fractions were combined according to the characteristic peaks of spectral absorption or liquid phase spectrum to obtain active ingredients F1, F2, F3, F4, F5; In the ethanol solution B, the concentration of ethanol is 5-15%; In the ethanol solution C, the concentration of ethanol is 25-35%; In the ethanol solution D, the concentration of ethanol is 70-80%; In the ethanol solution E, the concentration of ethanol is 90-100%; Preferably, the method for preparing the active ingredient of Ipomoea aquatica satisfies one or more of the following conditions: ① The Ipomoea aquatica ethanol extract is prepared by the following method: Mix Ilex polyphylla with 70-80% ethanol solution and extract to obtain; The concentration of the ethanol solution may be 75%; The ratio of the mass g of the Ipomoea aquatica to the volume ml of the 70-80% ethanol solution may be (10-40):1, for example (10-15):1; The extraction temperature may be 80-100°C, for example 95°C; The extraction method can be reflux extraction; The extraction time may be 2-10 hours, for example 2 hours or 6 hours; ② The alcohol extract of Ipomoea aquatica is obtained by dissolving the alcohol extract of Ipomoea aquatica in 5-15% ethanol solution; The ratio of the mass g of the Ipomoea aquatica ethanol extract to the volume mL of the 5-15% ethanol solution may be 1:(20-40), for example 1:30; ③ The mass ratio of the crude drug amount of I. polytrichum used in the I. polytrichum alcohol extract to the polyamide resin is 1:(1-5), for example 1:3; ④ The particle size of the polyamide resin is 60-80 mesh; ⑤ In the ethanol solution B, the concentration of ethanol is 10%; ⑥ The elution volume of the ethanol solution B is 5-7BV, for example 6BV; ⑦ In the ethanol solution C, the concentration of ethanol is 30%; ⑧ The elution volume of the ethanol solution C is 2-4BV, for example 3BV; ⑨ In the ethanol solution D, the concentration of ethanol is 75%; ⑩ The elution volume of the ethanol solution D is 5-7BV, for example 6BV; ⑾ In the ethanol solution E, the concentration of ethanol is 95%; ⑿ The elution volume of the ethanol solution E is 3-5BV, for example 4BV; ⒀The active ingredient F1, the active ingredient F2, the active ingredient F3, the active ingredient F4 and the active ingredient F5 are concentrated and optionally dried. 14 . An active ingredient of Ipomoea aquatica, comprising at least one of the active ingredient F1, the active ingredient F2, the active ingredient F3, the active ingredient F4 and the active ingredient F5 as claimed in claim 13 .

15. A method for preparing an active component E4', characterized in that: It includes the following steps: The water extract of Ilex polyphylla is subjected to macroporous adsorption resin chromatography, and after being eluted with water and ethanol solution A4' in sequence, the elution fractions of ethanol solution B4' and ethanol solution C4' are collected in sequence, combined, concentrated, and optionally dried to obtain the active component E4'; In the ethanol solution A4', the concentration of ethanol is 5-15%; In the ethanol solution B4', the concentration of ethanol is 25-35%; In the ethanol solution C4', the concentration of ethanol is 45-55%; Preferably, the preparation method of the active component E4' satisfies one or more of the following conditions: ① The water extract of Ixora solani is prepared by the following method: Mix Ipomoea aquatica with water and extract it to obtain the product; The mass ratio of the water calamus to the water may be 1:(10-40); The extraction temperature may be 100-120°C, for example 110°C; The extraction method can be reflux extraction; The extraction time may be 2-10 hours, for example 2 hours or 6 hours; ② The mass ratio of the crude drug amount of I. polyphylla used in the I. polyphylla water extract to the macroporous adsorption resin is 1:(1-5), for example 1:3; ③ The model of the macroporous adsorption resin is HPD100; ④ In the ethanol solution A4', the concentration of ethanol is 10%; ⑤ In the ethanol solution B4', the concentration of ethanol is 30%; ⑥ In the ethanol solution C4', the concentration of ethanol is 50%. 16 . An active component E4′, which is prepared by the preparation method of the active component E4′ according to claim 15 .

17. A water calamus extract, characterized in that The water caltrop extract contains one or more of the polysaccharide active ingredient as claimed in claim 2, the oligosaccharide active ingredient as claimed in claim 4, the aromatic acid active ingredient as claimed in claim 6, the iridoid glycoside active ingredient as claimed in claim 8, the phenylethanol glycoside active ingredient as claimed in claim 10, the active component E6 as claimed in claim 12, the water caltrop active ingredient as claimed in claim 14 and the active component E4' as claimed in claim 16.

18. A traditional Chinese medicine preparation comprising the Ipomoea aquatica extract as claimed in claim 17 and pharmaceutically acceptable excipients.